Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Experts Discuss Exciting Novel Therapies, Challenges in RCC

November 11th 2015

Robert Figlin, MD, and Daniel Petrylak, MD, discuss emerging agents in RCC they are excited about and what challenges still remain in treating the disease.

Dr. Figlin on Sunitinib for Patients With RCC

November 9th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, discusses newer methods of administering sunitinib (Sutent) to patients with renal cell carcinoma.

Atezolizumab Shows Promise of PD-1/PD-L1 Blockade in Metastatic Bladder Cancer

November 4th 2015

Immune checkpoint blockade has transformed the treatment paradigms of multiple advanced solid tumors-and bladder cancer is no exception.

LUGPA Meeting Focuses on Business and Clinical Challenges

November 4th 2015

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

Dr. Toni Choueiri on Cabozantinib and Nivolumab Combination in Kidney Cancer

November 3rd 2015

Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Dr. Richards on Unanswered Questions in Treating Bladder Cancer

November 3rd 2015

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

Motzer Discusses Nivolumab's Survival, QoL Benefits in RCC

November 2nd 2015

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

Petrylak Highlights Potential of PD-1/PD-L1 Inhibitors in Bladder Cancer

October 29th 2015

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

FDA Approval Sought for Cabozantinib in Advanced RCC

October 23rd 2015

Rolling submission of a new drug application for cabozantinib has been initiated for patients with advanced renal cell carcinoma who have received one prior therapy.

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

October 19th 2015

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

Renal Cell Carcinoma Vaccine Fails to Improve Outcomes

October 15th 2015

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

Ten Years After Sorafenib, TKIs Are Still Advancing Kidney Cancer Treatment

October 13th 2015

Robert Figlin, MD, discusses the evolution of TKIs in renal cell carcinoma, the novel agents and changes to established therapies he is most excited about, and the challenges that still remain.

In Kidney Cancer, Better Outcomes Demonstrated With Nephron-sparing Surgery

October 12th 2015

Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.

Are Surgery and Chemotherapy Sufficient to Treat Locally Advanced Bladder Cancer?

October 11th 2015

The challenge of pelvic failure following contemporary cystectomy has been engaged and the clinical trials to pursue the amelioration of this problem have commenced.

PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma

October 7th 2015

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.

Dr. Andrea Apolo on Treatment Challenges in Metastatic Bladder Cancer

October 2nd 2015

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses treatment challenges for patients with refractory, metastatic urothelial carcinoma.

FDA Schedules Advisory Meeting for MCNA in Bladder Cancer

October 2nd 2015

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-GuÃ©rin therapy.

Dr. Andrea Apolo on Avelumab in Metastatic Bladder Cancer

September 28th 2015

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses a phase 1b trial investigating avelumab, an anti-PD-L1 antibody, in patients with refractory, metastatic urothelial carcinomas.

Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma

September 27th 2015

Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.

Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell Carcinoma

September 27th 2015

Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).